Clearside Biomedical(CLSD) - 2024 Q4 - Annual Results

Revenue Performance - License and other revenue for Q4 2024 was $0.3 million, a decrease of 95.2$6.3 million in Q4 2023[6] - Full year 2024 license and other revenue totaled $1.7 million, a decrease of 79.5$8.2 million in 2023[10] Research and Development Expenses - R&D expenses for Q4 2024 were $4.2 million, down 33.1$6.3 million in Q4 2023, primarily due to lower clinical trial costs[6] - R&D expenses for the full year 2024 were $18.6 million, down 10.6$20.8 million in 2023[10] Net Loss - Net loss for Q4 2024 was $7.3 million, or$0.10 per share, compared to a net loss of $4.8 million, or$0.08 per share, in Q4 2023[6] - Net loss for the full year 2024 was $34.4 million, or$0.47 per share, compared to a net loss of $32.5 million, or$0.53 per share, in 2023[10] Cash Position - As of December 31, 2024, cash and cash equivalents totaled $20.0 million, sufficient to fund operations into Q4 2025[6] Regulatory and Clinical Developments - Successful End-of-Phase 2 meeting with the FDA confirmed plans for Phase 3 trials of CLS-AX in wet AMD[3] - New Drug Application for ARCATUS® (XIPERE®) for uveitic macular edema accepted for review in China[3] - Multiple medical meetings highlighted the advantages of Clearside's SCS Microinjector® in retinal disease treatments[3]